The mechanisms concerned in the abnormal prolongation of effect following suxamethonium administration, with reference to the use of neostigmine.
D006801:Humans; D009388:Neostigmine / Q000627:therapeutic use*; D010243:Paralysis / Q000209:etiology*; D013390:Succinylcholine / Q000009:adverse effects*
D009388:Neostigmine; D013390:Succinylcholine
NEOSTIGMINE/therapeutic use; PARALYSIS/etiology and pathogenesis; SUCCINYLCHOLINE/injurious effects